Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Sanofi (SNY) Receivables Refunds (2016 - 2026)

Sanofi's Receivables Refunds history spans 12 years, with the latest figure at $564.3 million for Q1 2026.

  • On a quarterly basis, Receivables Refunds rose 20.01% to $564.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $564.3 million, a 20.01% increase, with the full-year FY2025 number at $462.1 million, down 40.27% from a year prior.
  • Receivables Refunds hit $564.3 million in Q1 2026 for Sanofi, up from $462.1 million in the prior quarter.
  • Over the last five years, Receivables Refunds for SNY hit a ceiling of $773.7 million in Q4 2024 and a floor of $317.7 million in Q2 2024.
  • Historically, Receivables Refunds has averaged $489.0 million across 5 years, with a median of $462.1 million in 2025.
  • Biggest five-year swings in Receivables Refunds: surged 2679.59% in 2022 and later crashed 40.27% in 2025.
  • Tracing SNY's Receivables Refunds over 5 years: stood at $381.6 million in 2022, then grew by 10.25% to $420.7 million in 2023, then skyrocketed by 83.9% to $773.7 million in 2024, then crashed by 40.27% to $462.1 million in 2025, then rose by 22.11% to $564.3 million in 2026.
  • Business Quant data shows Receivables Refunds for SNY at $564.3 million in Q1 2026, $462.1 million in Q4 2025, and $581.0 million in Q3 2025.